Biogen Spin-Off Bioverativ to Acquire True North Therapeutics for up to US$825 M
By Natasha Piper
Pharma Deals Review: Vol 2017 Issue 6 (Table of Contents)
Published: 9 Jun-2017
DOI: 10.3833/pdr.v2017.i6.2255 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Bioverativ, the Biogen spin-off, has signed its first deal since it was formed in February 2017 with an agreement to acquire clinical-stage rare disease biotech, True North Therapeutics, for up to US$825 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS